Reports
Reports
Sale
The United States hereditary angioedema therapeutics market is expected to grow at a CAGR of 8.20% during the forecast period of 2024-2032, driven by the rising development of novel therapies, the favorable regulatory environment, and the growing patient awareness regarding hereditary angioedema diagnosis and treatment options in the region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hereditary angioedema (HAE) is a hereditary disorder in which the patient suffers from recurring attacks of severe swelling in body parts including hands, face, feet, and intestinal walls. It is caused by the deficiency or improper functioning of a protein that is a C1 inhibitor and can be life-threatening. There are numerous medications and therapies available to treat the condition and help control or prevent the swelling from occurring. In the United States, cases of hereditary angioedema are on the rise, which is fueling the United States hereditary angioedema therapeutics market demand.
Hereditary angioedema therapies have been progressing with time and now effective medications are available such as Garadacimab. Key players are continuously striving to innovate and develop better treatment options which also impacts the dynamics of the global hereditary angioedema therapeutics market . Patients depending on the therapies are receiving positive results which is ultimately resulting in the growth of the market. Unawareness about the disease can lead to misdiagnosis, and delay treatment. Organizations such as the United States Hereditary Angioedema Association are spreading awareness about the condition, its causes, and the treatments available, further supporting the expansion of the United States hereditary angioedema therapeutics market.
Home-based treatments are available for hereditary angioedema which have aided in reducing the seriousness of attacks and improving the quality of life of the patient. Factors such as the rising development of long-acting prophylactic therapies, increased regulatory approvals, and expanding pipelines for hereditary angioedema therapies are expected to bolster the market share in the forecast period.
Surge in FDA Approval of Hereditary Angioedema Drugs to Fuel the Market Demand
The surge in regulatory approvals of new therapies indicated for hereditary angioedema by the United States Food and Drug Administration (FDA) is projected to propel the market growth. For instance, in February 2023, Takeda Pharmaceuticals announced that its human monoclonal antibody TAKHZYRO® (lanadelumab-flyo) received clearance from the FDA for preventing hereditary angioedema (HAE) attacks in children aged 2 to 6 years, making it the first and only approved HAE prophylaxis treatment in this age category in the United States.
Moreover, in August 2023, the FDA also granted approval to Eugia Pharma Specialities Limited's (subsidiary of Aurobindo Pharma) generic version of Firazyr (icatibant injection) indicated for treating acute swelling attacks of hereditary angioedema in adults. The rising introduction of such therapies for HAE is likely to expand the range of available treatment options in the United States and boost the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is witnessing several trends and developments to improve the current scenario in the United States. Some of the notable trends are as follows:
Key Trends | Impact |
Increasing Focus on Prophylactic Treatments | The growing emphasis on prophylactic treatments that prevent hereditary angioedema attacks rather than just treating acute episodes is a major market trend that is set to augment market demand. Pharmaceutical companies are increasingly focusing on the introduction of long-acting prophylactic therapies that require less frequent dosing and offer superior clinical outcomes. |
Integration of Telemedicine and Digital Health Solutions | There is an increasing use of telemedicine for remote consultations and monitoring for managing chronic conditions like hereditary angioedema. Further, the rising adoption of digital health tools such as mobile apps for tracking patient symptoms and medication adherence is anticipated to elevate the market value. |
Rising Investments in Research and Development | The United States hereditary angioedema therapeutics market share is influenced by the rising investments in research and development by pharmaceutical companies, which are driving innovation and leading to a robust pipeline of HAE therapies. Several promising treatments are undergoing clinical trials and are poised to offer long-term or potentially curative options. |
Increased Awareness of Hereditary Angioedema | Increased educational initiatives and awareness campaigns by pharmaceutical companies and patient advocacy groups are resulting in heightened awareness about this rare genetic condition, which is likely to impact the diagnosis rates and demand for effective therapies. |
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Segmentation Based on Drug Type is Poised to Witness Substantial Growth
Based on the drug type, the market is segmented into C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors, among others. In children aged 12 years and above, hereditary angioedema is treated through drugs such as Kallikrin inhibitors, while in adults, C1 esterase inhibitors and B2 bradykinin receptor antagonists are used. C1 esterase inhibitors, which also act as an anti-inflammatory agent, have been leading the United States hereditary angioedema therapeutics market because it has the potential to treat other diseases along with hereditary angioedema.
Parenteral and Oral Routes Expected to Lead the Market Share
The market segmentation on the basis of route of administration includes parenteral and oral. The route of administration of medicine varies depending on the condition of the patient and the frequency of medication administration. The parenteral segment occupies a significant segment of the market as many therapies require urgent administration and faster impact. A parenteral route such as intravenous therapy is useful for patients already fitted with IV drips, while subcutaneous therapy can be effective for individuals who need quick administration. Long-term medication is most administered through oral forms to reduce the effect of the disorder.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The key regions of the United States market for hereditary angioedema therapeutics include the Northeast region, Southeast region, Midwest region, Southwest region, and West region. The Northeast region represents a considerable market share owing to the presence of leading pharmaceutical companies and biotechnology firms as well as the establishment of various specialized healthcare centers and clinics that focus on treating rare genetic disorders like hereditary angioedema. Other regions such as the Southeast and Midwest are also experiencing significant market growth driven by expanding healthcare facilities and increasing investment in biomedical research and innovation.
The key features of the market report include clinical trial analysis, grants analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited, founded in 1781, has its headquarters in Tokyo, Japan. It is a global pharmaceutical company that carries out research and innovates in medicine for the better health of patients worldwide. One of its key products is TAKHZYRO® (lanadelumab-flyo) which is a monoclonal antibody that helps in preventing hereditary angioedema attacks.
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. was established in 1986 with headquarters in North Carolina, United States. It is an American biotech company that deals with medicines, particularly oral drugs, that are prescribed for rare diseases. BioCryst is known for developing ORLADEYO® (berotralstat), the first oral, once-daily therapy for the prevention of HAE attacks and plays a significant role in the United States hereditary angioedema therapeutics market growth.
Sanofi
Sanofi S.A. founded in 2004 has its headquarters located in Paris, France. It is a healthcare company that manufactures vaccines and medicines for rare blood disorders, cardiovascular diseases, diabetes, and various other serious diseases. The company is actively engaged in R&D initiatives aimed at developing advanced therapies for hereditary angioedema.
CSL Behring LLC
The pioneering biotechnology company CSL Behring LLC. specializes in plasma-derived and recombinant therapies for rare diseases and is headquartered in Pennsylvania, USA. One of its leading assets for hereditary angioedema is Garadacimab, which received acceptance of its Biologics License Application (BLA) from the FDA in December 2023.
Other key players in the market include Pharming Group N.V., Cipla Inc., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., and Pharvaris B.V.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Type |
|
Breakup by Route of Administration |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Hereditary Angioedema Therapeutics Market Overview
3.1 North America Hereditary Angioedema Therapeutics Market
3.1.1 North America Hereditary Angioedema Therapeutics Market Historical Value (2017-2023)
3.1.2 North America Hereditary Angioedema Therapeutics Market Forecast Value (2024-2032)
3.2 United States Hereditary Angioedema Therapeutics Market
3.2.1 United States Hereditary Angioedema Therapeutics Market Historical Value (2017-2023)
3.2.2 United States Hereditary Angioedema Therapeutics Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 United States Hereditary Angioedema Therapeutics Market: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 United States Hereditary Angioedema Therapeutics Market Epidemiology Scenario and Forecast
7.1 Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence
7.1.2 Mortality
7.1.3 Treatment Seeking Rate
8 United States Hereditary Angioedema Therapeutics Market Landscape*
8.1 United States Hyperphosphatemia Therapeutics Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 United States Hyperphosphatemia Therapeutics Market: Product Landscape
8.2.1 Analysis by Drug Type
8.2.2 Analysis by Route of Administration
9 United States Hereditary Angioedema Therapeutics Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 United States Hereditary Angioedema Therapeutics Market: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 United States Hereditary Angioedema Therapeutics Market Segmentation (2017-2032)
12.1 United States Hereditary Angioedema Therapeutics Market (2017-2032) by Drug Type
12.1.1 Market Overview
12.1.2 C1-Esterase Inhibitor
12.1.3 Bradykinin B2 Receptor Antagonist
12.1.4 Kallikrein Inhibitor
12.1.5 Others
12.2 United States Hereditary Angioedema Therapeutics Market (2017-2032) by Route of Administration
12.2.1 Market Overview
12.2.2 Parenteral
12.2.3 Oral
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
14 Clinical Trial Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Grant Analysis
15.1 Analysis by Year
15.2 Analysis by Amount Awarded
15.3 Analysis by Issuing Authority
15.4 Analysis by Grant Product
15.5 Analysis by Funding Institute
15.6 Analysis by Departments
15.7 Analysis by Recipient Organization
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication Year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Strategic Initiatives
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Market Share Analysis by Top 5 Companies
19.2 Takeda Pharmaceutical Company Limited
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 BioCryst Pharmaceuticals, Inc.
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 Sanofi
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 CSL Behring LLC.
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 Pharming Group N.V.
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 Cipla, Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 Ionis Pharmaceuticals Inc.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 Attune Pharmaceuticals, Inc.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certifications
19.10 Adverum Biotechnologies, Inc.
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Mergers and Acquisitions
19.10.5 Certifications
19.11 Arrowhead Pharmaceuticals, Inc.
19.11.1 Financial Analysis
19.11.2 Product Portfolio
19.11.3 Demographic Reach and Achievements
19.11.4 Mergers and Acquisitions
19.11.5 Certifications
19.12 Pharvaris B.V
19.12.1 Financial Analysis
19.12.2 Product Portfolio
19.12.3 Demographic
19.12.4 Mergers and Acquisitions
19.12.5 Certifications
20 United States Hereditary Angioedema Therapeutics Market – Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.